Literature DB >> 2523100

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients.

D Abramowicz1, L Schandene, M Goldman, A Crusiaux, P Vereerstraeten, L De Pauw, J Wybran, P Kinnaert, E Dupont, C Toussaint.   

Abstract

High levels of tumor necrosis factor-alpha, interleukin-2, and gamma-interferon appeared in the circulation of kidney transplant recipients after the first injection of the monoclonal antibody OKT3. This initial injection was systematically followed by fever. The three cytokines were released in all patients (n = 9), with peak serum levels of tumor necrosis factor occurring 1 hr after OKT3 injection and those of interleukin-2 and gamma-interferon after 2 hr. Cytokines were not released after the second and third OKT3 injections, when CD3+ cells had disappeared from blood. These findings suggest that circulating cytokines are released by T cells after activation by OKT3. These cytokines are probably involved in the systematic reactions observed after injection of OKT3.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523100     DOI: 10.1097/00007890-198904000-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  54 in total

1.  Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment.

Authors:  G J Zlabinger; K M Stuhlmeier; R Eher; S Schmaldienst; R Klauser; A Vychytil; B Watschinger; O Traindl; J Kovarik; E Pohanka
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

2.  The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.

Authors:  Thomas Hünig
Journal:  Nat Rev Immunol       Date:  2012-04-10       Impact factor: 53.106

3.  Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts.

Authors:  Jing Li; Bo Zhou; Jianzhong Shentu; Li Du; Min Tan; Sheng Hou; Weizhu Qian; Bohua Li; Dapeng Zhang; Jianxin Dai; Hao Wang; Xu Zhang; Jianghua Chen; Yajun Guo
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

Review 4.  Tumor necrosis factor and immunopathology.

Authors:  P F Piguet; G E Grau; P Vassalli
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 5.  Perspectives in transplantation immunology 1991.

Authors:  D Kabelitz; M L da Silva Lobo; K Pechhold
Journal:  Klin Wochenschr       Date:  1991-09-03

Review 6.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 7.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 8.  New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.

Authors:  Hirofumi Ochi; Michal Abraham; Hiroki Ishikawa; Dan Frenkel; Kaiyong Yang; Alexandre Basso; Henry Wu; Mei-Ling Chen; Roopali Gandhi; Ariel Miller; Ruth Maron; Howard L Weiner
Journal:  J Neurol Sci       Date:  2008-09-18       Impact factor: 3.181

9.  Isotype-specific cross-linking of select human Fc gamma R isoforms triggers release of IL-6.

Authors:  A J Duits; L A Aarden; L K Ernst; P J Capel; J G van de Winkel
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

10.  In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.

Authors:  K J Parlevliet; I J ten Berge; S L Yong; J Surachno; J M Wilmink; P T Schellekens
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.